Chris Sloan advises a number of clients, including pharmaceutical manufacturers, health plans, providers, and patient groups on key policy issues facing the healthcare industry.
His particular areas of expertise include prescription drug pricing, economic and population impacts of policy, the Affordable Care Act, generic drugs, and biosimilars. Additionally, Chris is a recognized expert in the healthcare policy issues facing people living with HIV/AIDS and multiple sclerosis.
Chris’s economic analyses of key policy proposals and issues, including drug pricing and the repeal and replace efforts around the Affordable Care Act, have been featured in a wide range of publications, including the Wall Street Journal, the New York Times, the Washington Post, Politico, Axios, and Vox. Chris’s work has also been cited by policy makers on the Senate floor and by the Congressional Budget Office.
Chris has a BBA in economics and marketing from the College of William and Mary.